Cardellini M, et al. - In a cohort of patients affected by established atherosclerotic disease, researchers examined the role of the soluble form of suppression of tumorigenicity 2 (sST2) as a predictor of cardiovascular disease (CVD) and all-cause mortality. For this investigation, 399 study participants with atherosclerotic disease from the Tor Vergata Atherosclerosis Registry performed follow-up every year by phone interview. Researchers observed that sST2 plasma levels were significantly increased from normal glucose-tolerant patients to patients with a history of type 2 diabetes. They also observed a significant association of levels of sST2 with fasting plasma glucose, HbA1c, and HOMA. Findings showed that an elevated circulating level of sST2 was associated with increased CVD mortality and markers of metabolic dysfunction in this patient population.